Home/Filings/4/0001127602-19-002527
4//SEC Filing

Powell Lynne 4

Accession 0001127602-19-002527

CIK 0000882796other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 4:12 PM ET

Size

8.0 KB

Accession

0001127602-19-002527

Insider Transaction Report

Form 4
Period: 2019-01-18
Powell Lynne
Senior VP - CCO
Transactions
  • Exercise/Conversion

    Common Stock

    2019-01-18$3.22/sh+2,000$6,4402,000 total
  • Sale

    Common Stock

    2019-01-18$9.40/sh2,000$18,8000 total
  • Exercise/Conversion

    Emp. Stock Option (Right to Buy)

    2019-01-182,00091,427 total
    Exercise: $3.22From: 2017-05-23Exp: 2026-05-23Common Stock (2,000 underlying)
Footnotes (1)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.

Issuer

BIOCRYST PHARMACEUTICALS INC

CIK 0000882796

Entity typeother

Related Parties

1
  • filerCIK 0001631667

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:12 PM ET
Size
8.0 KB